|Post IPO Valuation|
|POST IPO FUNDING|
|Post IPO Equity, 11/12 ||$40M|
BioDelivery Sciences (“BDSI”®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.